BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26603642)

  • 1. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
    VanDevanter DR; Morris NJ; Konstan MW
    J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
    Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
    J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.
    VanDevanter DR; Flume PA; Morris N; Konstan MW
    J Cyst Fibros; 2016 Nov; 15(6):783-790. PubMed ID: 27139161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.
    VanDevanter DR; Pasta DJ; Konstan MW
    J Cyst Fibros; 2015 Nov; 14(6):763-9. PubMed ID: 25754096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
    Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
    J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
    West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States.
    Rubin JL; Thayer S; Watkins A; Wagener JS; Hodgkins PS; Schechter MS
    Curr Med Res Opin; 2017 Apr; 33(4):667-674. PubMed ID: 28058864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
    Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
    Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.
    Cogen JD; Whitlock KB; Gibson RL; Hoffman LR; VanDevanter DR
    J Cyst Fibros; 2019 Nov; 18(6):851-856. PubMed ID: 31147301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
    VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
    J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
    Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
    Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
    Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
    Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
    J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study.
    Somayaji R; Goss CH; Khan U; Neradilek M; Neuzil KM; Ortiz JR
    Clin Infect Dis; 2017 Jun; 64(12):1760-1767. PubMed ID: 28329304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
    Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
    Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
    [No Abstract]   [Full Text] [Related]  

  • 17. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
    Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
    Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.
    VanDevanter DR; Heltshe SL; Spahr J; Beckett VV; Daines CL; Dasenbrook EC; Gibson RL; Raksha J; Sanders DB; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):607-615. PubMed ID: 28438499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
    Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
    Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.
    Castner LM; Zimbric M; Cahalan S; Powell C; Caverly LJ
    J Cyst Fibros; 2021 Nov; 20(6):926-931. PubMed ID: 33612403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.